Flotek Raises 2026 Guidance Again on Continued Strength of International Sales

Flotek raised 2026 revenue guidance to $360M-$370M from $340M-$350M and Adjusted EBITDA guidance to $50M-$54M from $47M-$51M, driven by accelerating international chemistry demand. At the midpoints, the revised targets imply 54% revenue growth and 58% Adjusted EBITDA growth versus 2025. International chemistry revenue reached $10.6M in Q2, up more than 450% sequentially, and second-half international chemistry sales are expected to exceed $40M, supported by Saudi Arabia activity.

Analysis

The upgrade is economically meaningful because most of the incremental revenue appears to arrive late in the year, creating a higher run-rate entering 2027 rather than merely closing a modest annual shortfall. The key underwriting question is conversion: implied EBITDA on the incremental revenue is materially below the company-wide target margin, suggesting either launch/logistics costs, lower-margin international mix, or conservatism. A sustained international chemistry footprint could nevertheless re-rate FTK from a domestic oilfield-services niche toward a specialty production-chemicals/data platform, but only after contract duration, customer concentration, and cash conversion are verified.

Saudi exposure adds a non-linear operational risk that the headline EBITDA metric masks. Delivery disruptions, receivable collection, local-content requirements, or working-capital build can impair equity value even if revenue is recognized; reliance on an asset-based facility makes this more relevant than for cash-rich large-cap peers. The lack of a GAAP reconciliation and exclusion of contract-asset amortization mean investors should focus on operating cash flow, receivables days, inventory, and net debt—not the headline adjusted number—at the next results.

Near-term, the investor conference can extend momentum in a relatively illiquid small-cap, particularly if management discloses repeat orders or 2027 international revenue visibility. Contrarian risk is that the market extrapolates a single-region ramp as recurring global demand: if second-half international sales are project-based rather than consumables-like, the 2027 multiple should remain constrained. This is a company-specific signal with limited read-through to SLB, HAL, or BKR; those firms lack comparable revenue sensitivity to FTK's chemistry ramp.

Key Decisions for Investors

• Initiate only a tactical, small long FTK after confirming liquidity and current valuation versus the revised EBITDA midpoint; target a 1-3 month hold through the next earnings update. Add only if management provides customer concentration, contract term, and 2027 run-rate evidence at the September meetings.
• Use a 7-10% position-level stop from entry, or exit on evidence that second-half international revenue is below the implied run-rate. Thesis is falsified by receivables growth materially outpacing revenue, negative operating cash flow despite the EBITDA increase, or expanded ABL borrowings.
• Do not chase a conference-driven gap absent disclosures on cash conversion. A sharp move unsupported by disclosed backlog or repeat-order data is a potential fade because the incremental business is concentrated in a geopolitically exposed market and the revenue recognition/cash-collection profile is not established.
• Monitor Brent and Saudi operating conditions as risk indicators rather than trade signals: a sustained oil-price decline can pressure customer activity over 6-18 months, while regional logistics/security disruption could affect shipment timing within days to weeks.